Asia
It was a busy week for clinical trial updates for the first week of November. Here’s a look.
The trial demonstrated that patients receiving esaxerenone has a significantly higher Urine Albumin-to-Creatinine Ratio (UACR) of 22.1% compared to 4.0% on placebo.
New technology reduces amount of time spent preparing treatment plans in cancer genomic medicine by half in verification trials conducted with the Department of Hematology and Oncology
Although the results look very promising, there are still concerns similar to those seen with Sanofi’s Dengvaxia.
A scientific study of African populations discovers that the beta-amyloid gene is associated with an increased risk of the most common form of glaucoma
Reaffirms Biocon’s Capability to Manufacture Biosimilars for Patients in U.S.
Takeda will unload a portfolio of over-the-counter and prescription pharmaceutical products to Germany-based STADA for $660 million as the company continues to pare down debt from its $62 billion acquisition of Shire.
Daiichi Sankyo is taking Seattle Genetics to court over the technology the two companies used to develop antibody-drug conjugates during a partnership that spanned seven years.
AstraZeneca is significantly expanding its footprint in China with the establishment of a global research and development center in the country, as well as the launch of a $1 billion fund aimed at supporting that nation’s healthcare sector.
A*STAR’s Institute of Bioengineering and Nanotechnology has teamed up with the Singapore Institute of Advanced Medicine Holdings Pte Ltd to explore how to better tackle nasopharyngeal carcinoma, a type of head and neck cancer, through targeted proton therapy.
PRESS RELEASES